Centeno, Christopher J.
Berger, Dustin R.
Money, Brandon T.
Dodson, Ehren
Urbanek, Christopher W.
Steinmetz, Neven J. http://orcid.org/0000-0002-7844-9700
Article History
Received: 23 December 2021
Accepted: 18 July 2022
First Online: 6 August 2022
Declarations
:
: Approval of the clinical registry was obtained through the International Cellular Medicine Society Institutional Review Board (OHRP #IRB00002637).
: Informed consent was obtained from all individual participants included in the study.
: Consent to publish has been obtained from all participants<i>.</i>
: One or more of the authors has declared a potential conflict of interest. DRB, ED, and NJS are employed by Regenexx, LLC. CJC is a shareholder, patent holder, and chief medical officer of Regenexx, LLC, and an owner of the Centeno-Schultz Clinic. BTM and CWU are employed by the Centeno-Schultz Clinic.